Program
Quick Links
Keynote Speakers
Invited Speakers
Ms Heather Hodges
Due to unforeseen circumstances, Ms Heather Hodges is not able to deliver the Pioneer Lecture.
Associate Professor Nicholas Pocock
Mr Damion Stimson, Lowenthal Lecturer
Pre-Meeting Symposium Speakers
Professor Jeroen Bax
Professor Jeroen Bax is both Director of non-invasive imaging and Director of the echo-lab at the Leiden University Medical Center, The Netherlands.
His main interests include: clinical cardiology, heart failure, cardiac resynchronization therapy and the application of all different imaging modalities to these clinical fields.
Professor Bax has authored numerous papers and holds several positions in national and international scientific organizations. He is President of the ESC congress program committee for 2007-2008; and also serves on many editorial boards of different journals, including associate editor for the Journal of American College of Cardiology and Heart.
Valerie Cronin
Valerie Cronin was awarded fellowship status by the Society of Nuclear Medicine Technology Section in 2002 and served as its President in 2005. She is the Vice President of Imaging Services with the Catholic Health System in Buffalo, New York and a graduate of St. Bonaventure University. Currently she is pursuing a graduate degree in Health Services Administration.
Dr Ken Hossack
Dr Hossack trained in Cardiology in Australian and New Zealand. He subsequently held faculty positions at the University of Washington, Seattle and the University of Colorado, Denver.
Dr Hossack is a Past President of the Cardiac Society of Australia and New Zealand. Currently Dr Hossack is practicing as a consultant cardiologist at St Andrews Hospital, Brisbane and Allamanda Hospital, Southport.
Dr Kim Allan Williams
Dr Kim Allan Williams was born and raised in Chicago, and attended the College of The University of Chicago (1971 to 1975), followed by the University of Chicago's Pritzker School of Medicine (1975 to 1979), internal medicine residency at Emory University (1979 to 1982), and overlapping fellowships in Cardiology at the University of Chicago (1982 to 1985), Clinical Pharmacology (1984 to 1985), and Nuclear Medicine (1984 to 1986).
Dr Williams joined the faculty of the University of Chicago in 1986, specializing in clinical cardiology, nuclear medicine and nuclear cardiology. He is currently Professor of Medicine and Radiology and Director of Nuclear Cardiology at The University of Chicago School of Medicine. He is board certified in Internal Medicine, Cardiology, Nuclear Medicine, and Nuclear Cardiology.
Dr Williams has published numerous peer reviewed articles, monographs, book chapters, editorials, and review articles in the field of nuclear cardiology and minority health issues, with emphasis on education and innovations in perfusion imaging and quantitation of ventricular function. His current research is in selective adenosine receptor agonists, metabolic imaging with iodinated fatty acids and neuronal imaging in patients with congestive heart failure.
Dr Williams has served on numerous committees and boards at the national level, including the American Society of Nuclear Cardiology (ASNC), the American Heart Association (AHA), the American Medical Association (AMA), the American College of Cardiology (ACC), the Certifying Board of Nuclear Cardiology, and the Association of Black Cardiologists.
He is the immediate past President of ASNC, is the chair of the Coalition of Cardiovascular Organizations for 2006 to 2007, the Chair the Nuclear Medicine Section Council of the AMA Specialty Service Society from 2006 to 2007 as a delegate of the ACC and a representative of ASNC to the AMA, the chair of the ACC's Cardiovascular Imaging Collaborative. Through these positions he remains an active lobbyist for Medicare payment reform and patient access to medical imaging.
Mr Matthew Griffiths
Matthew trained in medical physics at QUT and worked for 7 years at Nuclear Medicine Department of St Vincent's Hospital, Sydney before moving to Brisbane in 1999 to under take a PhD investigating CT perfusion and its use with FDG PET in the study of micro metastasis. During the course of the PhD Matthew managed the installation of the GE MINItrace cyclotron for Southern Xray. Since 2003 Matthew has worked with the Department of Nuclear Medicine, Royal Brisbane and Women's Hospital. During this time he has been assisted in the set up of the QLD PET service being principally responsible for the planning, installation and operation of the GE PETtrace cyclotron.
Dr Aravind Ravi Kumar
Dr Aravind Ravi Kumar is a nuclear medicine physician. He has been working as a full time Nuclear Medicine Staff Specialist at the Royal Brisbane Hospital since January 2004, and has also been with the Statewide Queensland PET Service since its inception in late 2005.
Dr Rachael Moorin
Dr Rachael Moorin has a PhD in epidemiology/biostatistics and a Masters degree in Nuclear Medicine. She was as a chief Nuclear Medicine technologist for nine years (UK and NZ) before moving to Australia in 1999. In 2002 she won both the Radpharm and the Mallinkrodt awards at the ANZSNM Scientific Meeting. Rachael has presented research findings at international and national conferences; has first-authored 22 peer-reviewed publications; four government reports and has been successful in obtaining competitive funding for her research.
Associate Professor Nicholas Pocock
Nicholas Pocock graduated in medicine from Sydney University in 1978. In 1987 he became a Fellow of the Royal Australian College of Physicians and in 1989 gained his Doctorate in Medicine. He is currently a Senior Staff Specialist in the Department of Nuclear Medicine at St Vincent's Hospital, Darlinghurst and Associate Professor at the University of NSW. Dr Pocock's research interests include the epidemiology of osteoporosis and diagnostic measurements used in osteoporosis. Dr Pocock's work has resulted in membership of many working parties and clinical advisory groups to State and National medical and Government bodies, and to national and international medical publications. He has published widely on osteoporosis and bone densitometry and is currently on the Scientific Advisory Committees of the International Osteoporosis Foundation, The ANZBMS and Osteoporosis Australia.
Mr Travis Pearson
Mr Pearson graduated as a Nuclear Medicine Technologist from the University of Sydney in 1995. He worked as a Nuclear Medicine Technologist in Darwin and Adelaide before moving to the UK. Travis was Chief Technologist for East Kent Hospitals Trust 2002-4, before returning to Australia to take up current position as Director of Nuclear Medicine Technology at the Royal Brisbane & Women's Hospital. Currently, Travis is the ANZSNM Queensland branch Technologist SIG representative and has keen interest in training needs of Technologists to successfully adopt new scanning technologies.
Professor Andrew M. Scott
Professor Scott graduated in Medicine from the University of Sydney (MB BS - Hons), and trained in Internal Medicine, Nuclear Medicine and Tumour Immunology in Sydney, and at Memorial Sloan-Kettering Cancer Center, USA. His current appointments include Director, Ludwig Institute for Cancer Research, Melbourne Centre for Clinical Sciences; and Professor, Department of Medicine, University of Melbourne, and Director, Centre for PET, Austin Hospital. His research is focused on developing innovative strategies for targeted therapy of cancer with monoclonal antibodies and cell signalling inhibition, and in oncology applications in PET, both in staging and molecular characterisation of tumours. He has been involved in the preclinical development and first-in-man trials of six recombinant antibodies in cancer patients, and three antibodies from his program have recently been licensed to Biotech and Pharma companies. He is the Chair of the Commonwealth Government PET Data Collection Project. Professor Scott has over 160 peer reviewed publications, 10 invited reviews and 12 book chapters principally in cancer research and PET. He is also the Principal Investigator of research grants from NH&MRC, US National Institutes of Health, Australian Cancer Research Foundation, Cancer Council Victoria, Harry J Lloyd Foundation, Komen Foundation, and the Commonwealth Government Department of Health and Ageing.
Dr Andrew Southee
Dr Andrew Southee is a nuclear medicine physician with Northcoast Nuclear Medicine on the Sunshine Coast, Queensland. He graduated from UNSW (MBBS- Hons) and trained in internal medicine in Sydney at RNSH and RPAH, Newcastle, UCH London and subsequently nuclear medicine at RPAH and Harvard Boston.
Andrew was previously Director of Nuclear Medicine Hunter Area Health Service.
His special interests include teaching, sports medicine, cardiac stress testing, nuclear oncology and SPECT/CT.
Mr Damion Stimson
Damion Stimson joined the Queensland PET Service at Royal Brisbane & Women's Hospital in 2005 as a PET radiochemist. He has over 10 years experience in nuclear medicine, having worked with ANSTO's Australian Radioisotopes and National Medical Cyclotron, and later Sydney's Royal Prince Alfred Hospital in the development of SPECT and PET radiopharmaceuticals.
Ms Jocelyn Towson
Ms Jocelyn Towson has a Masters degree in Radiation Physics and Biology and has been the Radiation Safety Officer at RPAH since 1985. Her work includes practical protection measures, informed comment on radiation dose and risk, regulatory requirements, training and quality assurance with regard to radiation safety in nuclear medicine.
Professor J. Harvey Turner
Consultant Physician to general medical inpatients and Director of Nuclear Medicine, Fremantle Hospital since 1976 and Foundation Director Australian Institute Radiochemical Engineering and Chairman Australian Radionuclide Therapy Oncology Group, Founding Chairman World Radiopharmaceutical Therapy Council of World Federation Nuclear Medicine Biology, chaired the inaugural World Congress Radionuclide Therapy Summit 2006.
Dr Myles Webb
Dr Myles Webb is a Nuclear Physician at The Prince Charles Hospital in Brisbane and is a partner in a private nuclear medicine practice also at The Prince Charles Hospital. Myles is a medical graduate of The University of Queensland and completed his physician training at The Royal Brisbane and Women's hospital. Myles did 2 years of nuclear medicine training at The Royal Brisbane and Women's hospital and completed his training along with PET training at The Hammersmith and Charing Cross Hospital's in London in 2003. Myles has an interest in nuclear cardiology, vasculitis and PET and has helped write a textbook chapter on PET findings in vasculitis.
Myles is an Associate Lecturer for the University of Queensland Medical School and is a Council member of the ANZAPNM. Since Myles started working at The Prince Charles Hospital in 2003, he has been actively involved in postgraduate medical teaching. The advances in gamma camera technology have been a driving force for Myles to help establish cross sectional anatomy training for physicians and Myles was the co-ordinator for the first cross sectional anatomy course in 2006.
Mr David Woods
David Woods is the Principal Health Physicist at the Australian Nuclear Science and Technology Organisation.
David has an MSc in Radiological Health and Safety and a BSc(Hons) in Physics. He has 30 years experience in operational health physics and is Manager, Radiation Protection Services, at ANSTO. He is a Fellow of ARPS and Lead Country Coordinator for the IAEA/RCA Radiation Protection Project in the Asia/Pacific Region.
Dr Joseph Wong
Dr Joseph Wong is a nuclear medicine physician with Northcoast Nuclear Medicine in Queensland. He also manages a private bone densitometry practice at Newmarket in North Brisbane. Dr Wong is on the Bone Densitometry Committee of the ANZBMS and has Certification in Clinical Densitometry with the ISCD. His research interests include performance of DEXA instruments, and clinical evaluation of bone density and body composition. Dr Wong is a Senior Lecturer at the School of Medicine in the University of Queensland. He is the current President of the ANZAPNM and a past President of the ANZSNM.
Mr Paul Cardew
Paul Cardew is the Chief Physicist with the Nuclear Medicine Division of the Hunter New England Imaging Service based at John Hunter Hospital, Newcastle, NSW. Having worked as physicst in radiation protection, radiotherapy and radiology prior to switching to Nuclear Medicine, he has a keen interest in the integration of imaging modalites.
Dr Richard Smart
Richard Smart obtained his initial training in Medical Physics at the Sheffield Royal Infirmary, UK, where he completed his PhD through the University of Sheffield. He is currently the Chief Physicist and Radiation Safety Officer at St George Hospital and holds a conjoint Associate Professor appointment with the University of NSW.
Provisional Program
Friday, 2 May
- Pre-Meeting Symposium at Seaworld Nara
- ANZAPNM Council Meeting
- Gold with Gordon at Royal Pines
Saturday, 3 May
- ANZSNMT Symposium
- ANZAPNM Symposium
- Physicists SIG
- Nurses SIG
- Radiopharmacists SIG
- Welcome Reception
Sunday, 4 May
- Plenary Sessions
- Lowenthal Lecture
- Concurrent Sessions, including Mallinckrodt Award
- Nuc's Party
Monday, 5 May
- Plenary Sessions
- Concurrent Sessions, including APZAPNM Registrar and ANSTO Awards
- ANZSNM AGM
- Pioneer Lecture
- Gala Dinner
Tuesday, 6 May
- Plenary Sessions
- Concurrent Sessions
- Meeting Highlights
- Conference Close
Awards
Poster Prizes
ANSTO Nuclear Medicine Award
ANZAPNM Registrar Award
Mallingckrodt Award for Nuclear Medicine Technologist
Radpharm Award
Poster Prizes
Delegates are invited to present their scientific data in poster form and vie for three prizes. The 'Global Medical Solutions Poster Prize' will be awarded to the poster judged to be of the most outstanding scientific merit. There will also be a "Convenor's Choice" Poster Prize for the poster with the best images. The 'Radiology SA Rookie Poster Prize' will be awarded to the best poster submitted by a trainee in any discipline relevant to Nuclear Medicine - medical, technologist, physics or radiopharmacy.
ANSTO Nuclear Medicine Award
RULES
1. The Award will be made for significant innovation in research or clinical practise in the field of Nuclear Medicine. It will be presented as a paper at the Conference. It must also have been accepted for oral or poster presentation at an international medical speciality meeting, or for publication in an international peer reviewed journal. The objective of the award is to highlight the high calibre of Australian Nuclear Medicine and ANSTO's role in supporting it to a diverse an audience as possible - particularly the Nuclear Medicine referral base.
2. Entrants for the Award may be from any discipline within the field of Nuclear Medicine. The entrant must be a financial member of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) of at least six months standing.
3. The Award is not open to employees of ANSTO, or for work or research carried out whilst an employee of ANSTO.
4. The material shall be presented as an oral paper at the Annual Meeting of the ANZSNM.
5. Candidates must provide a statement countersigned by his or her department head indicating the extent of assistance received during the course of the work. This statement plus four copies of the full manuscript shall be in the hands of the Scientific Programme Organiser at least four weeks prior to the Conference to enable short-listing and preliminary review of the work. All candidates will be notified of the outcome of this process at least one week before the conference..
6. The recipient of the Award must undertake to submit the written paper to the Editor of the ANZSNM Journal for publication within six months of receiving the Award. The manuscripts of non-winning entrants will be destroyed.
7. Within six months of the completion of the approved travel, the winner must make a technical report of 1500-2000 words to the Editor of the ANZSNM Journal for publication.
JUDGING
Papers submitted for the Award shall be judged by a panel of one Senior Researcher and one physician nominated by the Society and a representative of ANSTO. The judges must not be drawn from the same department as any candidate. The panel reserves the right not to make an award if it is deemed the standard is not sufficiently high. A simple majority vote of the panel (2) will govern all decisions. The panel shall meet prior to the first presentation to ensure that the judging criteria are understood.
The assessment for the Award will be on the basis of the following:
(a) Significance and merit of the data or procedure = 40%
(b) Scientific method of investigation or development = 30%
(c) Originality = 20%
(d) Presentation skills = 10%
THE AWARD
The Award will be for $3000 for documented expenses incurred to attend an international nuclear medicine meeting, eg. the Society of Nuclear Medicine or the European Association of Nuclear Medicine.
The successful applicant must provide ANSTO with his or her travel itinerary within six months of winning the Award.
ANZAPNM Registrar Award
GUIDELINES
The Award shall be known as The ANZAPNM Reigstrar Award. The Award is open to advanced trainees in nuclear medicine or to full-time research registrars in nuclear medicine, as part of a training program approved by the Joint Specialist Advisory Committee of the Royal Australasian College of Physicians (RACP) and the Royal Australian and New Zealand College of Radiologists (RANZCR). Recently qualified trainees may enter, provided that the work for the presentation was carried out during the period of training and is presented at the first Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM) after completion of training. Entries are limited to one per candidate. Entrants must be financial members of the ANZSNM at the time of presentation.
The Award is for work that provides new and significant data of clinical and Scientific merit and involves the use of nuclear medicine techniques.
The data will be presented as an oral paper at the Annual Scientific Meeting of the ANZSNM. Notification should be given with the submission of the abstract that the presenter wishes to be considered for the Award.
The candidate must provide a statement, countersigned by his or her department head, indicating the extent of assistance received during the course of the work. This statement plus four copies of the paper must be received by the ANZAPNM Secretariat no later than two weeks prior to the ANZSNM Scientific Meeting.
The recipient of the Award shall provide a summary of the paper to both the ANZSNM and to the ANZAPNM Secretariat, for publication in the ANZSNM Journal and the ANZAPNM Newsletter and/or website. Successful candidates wishing to submit their work to a peer-reviewed medical journal may be permitted to do so after consulting with the ANZAPNM President.
Papers submitted for the Award shall be judged by a panel of two physicians and one scientist, nominated by the ANZAPNM. Each member of the juding panel shall declare any conflict of interest, and shall not judge any paper submitted by a candidate from his/her department. The Award will be made at the discretion of the judges.
The weightings for the Award will be as follows:
(a) Significance and merit of the data - 40%
(b) Scientific method of the investigation - 30%
(c) Oral presentation skills - 20%
(d) Originality - 10%
The Award will be for travel up to A$3,000 to enable attendance at an approved nuclear medicine meeting. All details and bookings for the trip shall be finalised by 31 March of the year following presentation of the Award.
The judging panel reserves the right not to make an Award in any year.
The Award is administered by the ANZAPNM. All correspondence relating to the Award should be made to the ANZAPNM Secretariat, P O Box 73, Balmain NSW 2041 Australia.
(Published ANZ Nuclear Medicine June 2003)
Mallinckrodt Award for Nuclear Medicine Technologist
INTRODUCTION
The Mallinckrodt Award will be held in conjunction with the Annual Scientific Meeting (ASM) of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM). Its aim is to foster the spirit of innovation and progress in nuclear medicine.
The Award will be provided for an oral scientific or technical paper presented by an accredited nuclear medicine technologist.
DEFINITION FOR THE PURPOSE OF THIS AWARD
(a) Technologist: A financial member of the ANZSNM who is employed as an accredited technologist in the field of nuclear medicine or who has been granted interim accreditation and who has been a financial member of the society for at least six months.
(b) Scientific or technical paper: A paper constructed in the following format. Objectives, Materials/Methods, Results, Discussion and Conclusions
ENTRIES FOR THE AWARD
This Award will be made on investigational or other work presented orally at the ASM by the entrant.
Entries will be considered on their value in improving knowledge in any aspect of nuclear medicine. While the study need not be totally original, considerable attention will be paid to the basic idea, to the individual effort and to the lack of dependence on non-technical aspects such as scan interpretation or clinical assessment. The fundamental requirements of any scientific paper, such as clarity of description of the studied problem in the context of published data, critical evaluation of results, utilisation of statistical or other relevant methodologies, as well as the presentation itself, will be taken into account. Acknowledgment of people or agencies that have contributed substantially to the work must the included.
A candidate for the Award must submit an abstract for the ASM as with any other paper. Submission of abstracts must be in accordance with the requirements of the ASM.
All papers submitted for the award will be considered on their merits as to eligibly and final acceptance.
An accredited technologist entering for the Award shall provide a personally signed statement countersigned by the department head, indicating the extent of assistance given by others so that the judges can make an assessment of the proportion of the work done by the author(s) of the paper. This statement, plus an electronic copy and one hard copy of the full manuscript, shall be in the hands of the Professional Conference Organiser (PCO) at least three weeks prior to the beginning of the Conference.
The audience will be informed that the paper is an entry for the Award.
The recipient(s) of the Award must undertake to submit a copy of the manuscript to the Editor of the Society's Journal for publication within two months of winning the Award. All manuscripts of non-winning entrants submitted to the PCO will be destroyed.
MANUSCRIPT SUBMISSION FORMAT: Submitted on disc or by e-mail in Microsoft word. Forward one complete hardcopy. Each A4 page should be double spaced with font size of at least 10 points and paragraph indentation of at least 5 spaces.
Components of each manuscript must be submitted in the following order:
1. Title Page
2. Abstract
3. Text
4. Acknowledgments
5. References
6. Tables & Figure legends Pages should be number consecutively
FINANCIAL SUPPORT
If a candidate for the Award requires financial support to attend the ASM in order to present a paper, application should first be made to the employer. If this is unsuccessful, and the entrant wishes to seek support from the Society, application should be made to the local branch of the Society at least two months prior to the ASM.
Applications will be considered by each branch and a decision made on which author or authors it wishes to recommend that financial support be given. Such a decision will usually be based upon a presentation of the paper at a local branch meeting. The decision should then be forwarded to the Secretary not less than one month prior to the ASM.
The Executive of the Society will decide on the amount of money which the Society could provide and will advise the candidate through the Society. (The local branch is free to support a candidate with additional assistance.)
JUDGING
The judging panel shall consist of three society members drawn, where practicable, from the Accreditation Board of the Society. One should be the President of the ANZSNM or their nominee, who shall act as Chairman. One of the two remaining judges shall be a nuclear medicine technologist for whom no conflict of interest can be identified. A judge must not belong to the same department as a candidate.
The criteria upon which judgement will rely shall include the following (percentages are maxima):
(a) The value of the paper as a contribution to nuclear medicine technology - 25%
(b) The extent of direct assistance the author(s) receive from supervisors or other individuals
(c) The content of the paper (accuracy, logic, statistical consideration, originality, etc) - 50%
(d) The technique of presentation (clarity, expression, quality and use of slides, timing, handling of questions, etc) - 25%
The judges will have discretion as to whether an Award will be made. The successful candidate will receive a suitably inscribed trophy.
AWARD
The Award will consist of one return economy class airline ticket for the purpose of attendance at a major international scientific meeting such as the Annual Scientific Meeting of the Society of Nuclear Medicine or the European Association of Nuclear Medicine. In the case of multiple author entries, the Award will be shared.
A submission must be made to the Secretary of the ANZSNM outlining the proposed use of the Award ticket.
Following the completion of the approved travel, the winner(s) must make a technical report of 1500-2000 words to the Secretary for publication in the Society's Journal. This should be completed within six months of the travel.
Radpharm Award
RADPHARM Case Presentation Award Rules 1999
(Reviewed March 1999)
1. The RADPHARM Technologist Case Presentation Award, hereafter termed the Award, will be held in conjunction with the Annual Scientific Meeting (ASM) of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), hereafter termed the Society.
2. Entries to the Award will be Nuclear Technologists employed within the field of Nuclear Medicine. Such entries will have been financial members of the Society for at least 6 months. Students undertaking an approved course of studying Nuclear Medicine are also eligible to enter.
3. The Award will be made for an Oral Case Presentation of a single (One ( 1)) patient's study(s) performed within Nuclear Medicine workplace.
4. The Award comprises two (2) parts. An initial Sponsorship (part 1 ) will be made to the winning entrant in the Home State. The Award (Part 2) will be made at the Technologist Symposium of the ASM.
Previous State Winners may submit and present further case studies, however, they will be ineligible to become the State Winning Entrant for a period of two years.
5. Entrants to Part I and Part 2 of the Award must present their case study in the same year, the case unchanged in the intervening period.
6. PART l - Sponsorship
6.1 Entries for the Award are to present an oral case study in their Home State or in New Zealand (NZ).
The Home State/NZ shall be the region in which:
a) the entrant is employed/studying in the field of Nuclear Medicine and,
b) where the case study was obtained.
6.2 The Home States in Australia shall deemed one of the following:
a) NSW (including ACT)
b) QLD
c) SA(including NT)
d) TAS
e) VIC
f) WA
6.3 Entrants to the Award are to present to the State/NZ Branch representative of the ANZSNM Technologist Group (ANZSNMT) a signed statement, countersigned by the department head indicating the extent of assistance received during the course of the case study work. In the case of a video presentation this statement should also confirm that the presentation was performed in accordance with the Rules and that the video has not been edited.
6.4 The winner of the State/NZ sponsoring will be required to provide this statement to the Hon. Secretary ANZSNMT on submission of the abstract to Part 2 of the Award.
6.5 Entrants to the Award (Part l and 2}, are to present their case study in a maximum of ten (10) minutes. The total presentation time will be divided as:
a) oral case presentation -7 minutes (maximum)
b) question time -3 minutes (maximum)
6.6 The State Branch/NZ Branch representative of the ANZSNMT will organise a venue and time for the presentation of case by entries to the Award, in the February immediately prior to the ASM of the Society each year. Entrants to the Award who are normally located remotely from the presentation venue may submit a video presentation, performed before an audience of professional healthcare colleagues, to be viewed by the audience and judges at the presentation meeting. The current entrant will be available via telephone link to answer questions from the presentation meeting.
6.7 Judges for the State/NZ sponsorships shall determine the winning case presentation. The home State/NZ entrant awarded the sponsorship shall be termed a National or NZ finalist.
6.8 The State/NZ sponsorships shall be Judged by panel of three (3) Nuclear Medicine Technologists. The panel will be nominated by the State Branch representative of the ANZSNMT. The panel must include the nominated State representative of the ANZSNMT. All panel members are to be full financial members of the Society, and eligible for accreditation. Where possible the judging panel should not be drawn from the same workplace/department as any entry to the award.
6.9 If there is only one case presentation within a State/NZ, the case study must be presented to a panel of three (3) Nuclear Medicine Technologists at a presentation night or Branch meeting. The panel of judges must judge whether the presentation is worthy and hence eligible for the Sponsorship. If judged to be unworthy, there will be no winner from that Home State or NZ.
6.10 The National and NZ finalist will be sponsored by RADPHARM to A$500 towards attending the Technologist Symposium of the ASM, to present their winning case study. Winners of Part 1 Sponsorships, are the only entrant to Part 2 of the Award.
7. PART 2 - The Award
7.1 National and NZ finalists must submit an abstract of their winning case presentation for the Technologist Symposium as with any paper. Submission of abstract must be in accordance with the requirements of the ASM.
7.2 The audience wi]l be informed that the presentation is an entry for the RADPHARM Technologist Case Presentation Award
7.3 The Award will be judged by a panel of seven (7) Nuclear Medicine Technologist representatives, each nominated by their State/NZ Branch representative of the ANZSNMT. The judging panel must not be drawn from the same department/workplace as entry to the Award.
8. The Sponsorship and the Award will be decided on the following criteria with value specified,
a) - Originality
b) - Presentation
c) - Content (Correlative Investigations may be used.)
d) - Interest/Value of paper to Nuclear Medicine
e) - Contribution of Nuclear Medicine to patient management.
9. The RADPHARM Technologist Case Presentation Award will be presented at the conclusion of the Conference.
10. The recipient of the Award should provide to the ANZSNMT Honorary Secretary, an appropriate summary of the case study presentation for publication in the ANZSNMT Newsletter.
Developing Countries
EUROPE
Albania
Armenia
Azerbaijan
Bosnia and Herzegovina
Croatia
Georgia
Gibraltar
Macedonia (former Yugoslav Republic)
Malta
Moldova
Slovenia
Turkey
Yugoslavia, Federal Republic
AFRICA
North of Sahara
Algeria
Egypt
Libya
Morocco
Tunisia
South of Sahara
Angola
Benin
Botswana
Burkina Faso
Burundi
Cameroon
Cape Verde
Central African Republic
Chad
Comoros
Congo, Republic
Congo, Democratic Republic
Cote d'Ivoire
Djibouti
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Kenya
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mayotte
Mozambique
Namibia
Niger
Nigeria
Rwanda
St. Helena
Sao Tome & Principe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sudan
Swaziland
Tanzania
Togo
Uganda
Zambia
Zimbabwe
North & Central AMERICA
Anguilla
Antigua & Barbuda
Aruba
Barbados
Belize
Costa Rica
Cuba
Dominica
Dominican Republic
El Salvador
Grenada
Guatemala
Haiti
Honduras
Jamaica
Mexico
Montserrat
Netherlands Antilles
Nicaragua
Panama
St. Kitts and Nevis
St. Lucia
St. Vincent & Grenadines
Trinidad and Tobago
Turks & Caicos Island
Virgin Islands (UK)
SOUTH AMERICA
Argentina
Bolivia
Brazil
Chile
Colombia
Ecuador
Guyana
Paraguay
Peru
Suriname
Uruguay
Venezuela
ASIA
Afghanistan
Bangladesh
Bhutan
Burma
Cambodia
China, (excl. H.K.)
East Timor
India
Indonesia
Kazakhstan
Korea, Democratic Republic
Korea, Republic
Kyrgyz Republic
Laos
Macao
Malaysia
Maldives
Mongolia
Nepal
Pakistan
Philippines
Sri Lanka
Tajikistan
Thailand
Turkmenistan
Uzbekistan
Vietnam
MIDDLE EAST
Bahrain
Iran
Iraq
Jordan
Lebanon
Oman
TERRITORIES ADMINISTERED BY THE PALESTINIAN AUTHORITY
Saudi Arabia
Syria
Yemen
PACIFIC
Cook Islands
Micronesia, Federated States
Fiji
Kiribati
Marshall Islands
Nauru
New Caledonia
Niue
Northern Marianas
Palau Islands
Papua New Guinea
French Polynesia
Samoa
Solomon Island
Tokelau
Tonga
Tuvalu
Vanuatu
Wallis & Futuna